Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has entered into an agreement for the acquisition of the plasma collection center and certain related rights and assets from the privately-held Blood and Plasma Research, Inc (B&PR) of Beaumont, TX, USA. B&PR’s collection facility primarily specializes in the collection of hyper-immune plasma used for the Anti-D immunoglobulin, which is manufactured by Kamada and distributed in international markets. B&PR’s plasma collection center is one of the few FDA-licensed centers in the U.S. providing the raw materials required for this product.
Read the full article: Kamada Acquires FDA-Licensed Plasma Collection Center from Blood and Plasma Research, Inc. in Texas, USA //
Source: https://www.globenewswire.com/news-release/2021/02/01/2167147/0/en/Kamada-Acquires-FDA-Licensed-Plasma-Collection-Center-from-Blood-and-Plasma-Research-Inc-in-Texas-USA.html